跳至主要内容
临床试验/NCT01601652
NCT01601652已完成1 期

Open Label, Compassionate Use Protocol of an Intravenous Fish Oil Emulsion in Infants With Cholestasis

Arthur J De Lorimier1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2011年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
12
试验地点
1
主要终点
Normalization of Conjugated Bilirubin (Conjugated Bilirubin < 2 mg/dL)

研究概览

简要总结

The study will evaluate the safety and efficacy of an intravenous fish oil emulsion (omegaven) in infants with parenteral nutrition associated cholestasis.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 1 Year(Child)
性别
All
接受健康志愿者

入选标准

  • Cholestasis defined as either
  • serum bilirubin > 2mg/dL (two measurements at least 8d apart) that has not responded to 4 weeks of intralipid being reduced to 1 g/kg/d and trace minerals being limited to twice weekly, OR
  • serum bilirubin > 6 mg/dL (single measurement) and rising, in the absence of proven or suspected sepsis

排除标准

  • Age > 1y at time that omegaven is started
  • Not expected to survive at least 30 days
  • Fish allergy in a first degree relative
  • Hemodynamic instability
  • Coagulopathy
  • Not likely to require PN for > 30d
  • Not expected to survive > 30d

研究组 & 干预措施

Omeagven

Experimental

干预措施: Omegaven (Drug)

结局指标

主要结局

Normalization of Conjugated Bilirubin (Conjugated Bilirubin < 2 mg/dL)

时间窗: approximately for 4 months

次要结局

  • Liver Transaminases(approximately for 4 months)

研究者

发起方
Arthur J De Lorimier
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Arthur J De Lorimier

Associate Professor of Pediatrics

University of California, Davis

研究点 (1)

Loading locations...

相似试验